Your browser doesn't support javascript.
Factors associated with high antibody titer following coronavirus disease among 581 convalescent plasma donors: A single-center cross-sectional study in Japan.
Suzuki, Tetsuya; Asai, Yusuke; Ide, Satoshi; Fukuda, Saori; Tanaka, Akihito; Shimanishi, Yumiko; Takahashi, Kozue; Terada, Mari; Sato, Lubna; Sato, Mitsuhiro; Inada, Makoto; Yamada, Gen; Miyazato, Yusuke; Akiyama, Yutaro; Nomoto, Hidetoshi; Nakamoto, Takato; Nakamura, Keiji; Togano, Tomiteru; Morioka, Shinichiro; Kinoshita-Iwamoto, Noriko; Saito, Sho; Kutsuna, Satoshi; Ohmagari, Norio.
  • Suzuki T; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan.
  • Asai Y; AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ide S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan.
  • Fukuda S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Tanaka A; Clinical Laboratory Department, National Center for Global Health and Medicine, Tokyo, Japan.
  • Shimanishi Y; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Takahashi K; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Terada M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Sato L; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Sato M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Inada M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Yamada G; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Miyazato Y; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Akiyama Y; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Nomoto H; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan.
  • Nakamoto T; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Nakamura K; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Togano T; Department of Hematology, National Center for Global Health and Medicine, Tokyo, Japan.
  • Morioka S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan.
  • Kinoshita-Iwamoto N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan.
  • Saito S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan.
  • Kutsuna S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Department of Infection Control, Graduate School of Medicine, Osaka University, Japan. Electronic address: sonare.since1192@gmail.com.
  • Ohmagari N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Emerging and Re-emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japa
J Infect Chemother ; 28(2): 206-210, 2022 Feb.
Article in English | MEDLINE | ID: covidwho-1472052
ABSTRACT

INTRODUCTION:

The ability to predict which patients with a history of coronavirus disease (COVID-19) will exhibit a high antibody titer is necessary for more efficient screening of potential convalescent plasma donors. We aimed to identify factors associated with a high immunoglobulin G (IgG) titer in Japanese convalescent plasma donors after COVID-19.

METHODS:

This cross-sectional study included volunteers undergoing screening for convalescent plasma donation after COVID-19. Serum anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S-protein IgG antibodies were measured using a high-sensitivity chemiluminescence enzyme immunoassay.

RESULTS:

IgG antibodies were measured in 581 patients, 534 of whom had full information of selected independent variables. Multiple linear regression analysis revealed that increasing age (1.037 [1,025, 1.048]), days from symptom onset to sampling (0.997 [0.995, 0.998]), fever (1.664 [1.226, 2.259]), systemic corticosteroid use during SARS-CoV-2 infection (2.382 [1.576, 3.601]), and blood type AB (1.478 [1.032, 2.117]) predict antibody titer.

CONCLUSION:

Older participants, those who experienced fever during infection, those treated with systemic corticosteroids during infection, those from whom samples were obtained earlier after symptom onset, and those with blood type AB are the best candidates for convalescent plasma donation. Therefore, these factors should be incorporated into the screening criteria for convalescent plasma donation after SARS-CoV-2 infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Antibodies, Viral Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Asia Language: English Journal: J Infect Chemother Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: J.jiac.2021.10.012

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Antibodies, Viral Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Asia Language: English Journal: J Infect Chemother Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: J.jiac.2021.10.012